10x Genomics, Inc.
TXGHealthcareNASDAQHealth Information Services · Last scanned Jun 3, 2026
Scan Results
Daily timeframe10x Genomics, Inc. develops and sells instruments, consumables, and software for analyzing biological systems in the United States, rest of the Americas, Europe, the Middle East, Africa, China, and the rest of the Asia. With a market capitalization of $3.90B, it sits in mid-cap territory. The company offers Chromium platform, a single cell portfolio that enables analysis of individual biological components, as well as includes microfluidic chips and related consumables, Chromium X Series, and Chromium instruments; and QuantumScale single cell RNA and single cell methylation kits.
Market Cap
$3.90B
Beta
2.05
P/E (TTM)
—
P/E (Fwd)
153.55
EPS (TTM)
$-0.17
EPS (Fwd)
$0.20
ROE
-3.0%
ROA
-4.5%
Cash
$539.8M
Total Debt
$81.4M
Free CF
$124.5M
52W Change
228.8%
Annual Financials
Cash vs Debt
10x Genomics, Inc. holds $539.8M in cash against $81.4M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow comes in at $124.5M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. Return on equity stands at -3.0%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has grown from $516.4M (2022) to $642.8M (2025), reflecting a 24% increase over the period.
10x Genomics, Inc.'s elevated beta suggests the stock experiences more pronounced price movements than the overall market, which increases both upside potential and downside risk. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing TXG.